Comparative Pharmacology
Head-to-head clinical analysis: NEBCIN versus NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEBCIN versus NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE.
NEBCIN vs NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.
Neomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and cell death. Dexamethasone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
3-6 mg/kg/day IV in 2-3 divided doses every 8-12 hours; adjust based on serum levels and renal function.
1-2 drops of ophthalmic solution (neomycin 3.5 mg/mL and dexamethasone 1 mg/mL) or ointment (neomycin 3.5 mg/g and dexamethasone 1 mg/g) into the affected eye(s) every 4-6 hours; in severe cases, every 1-2 hours initially and tapered. For otic use: 3-4 drops into the affected ear(s) 3-4 times daily. Topical: apply thin layer to affected area 1-3 times daily.
None Documented
None Documented
Terminal elimination half-life is 2-3 hours in patients with normal renal function. Prolonged to 24-48 hours in anuria. Clinical context: Dosing interval adjustment required in renal impairment to avoid toxicity.
Neomycin: 2-3 h (topical/ophthalmic absorption minimal; if significant, prolonged in renal impairment). Dexamethasone: 4-6 h (ophthalmic, systemic if absorbed).
Renal excretion of unchanged drug accounts for >90% of elimination. Approximately 10% is excreted in bile.
Renal: neomycin ~30-80% unchanged; dexamethasone phosphate ~80% as free/free glucuronide metabolites. Fecal: negligible.
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic